Page last updated: 2024-10-27

foscarnet and HIV

foscarnet has been researched along with HIV in 28 studies

Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance."9.12Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006)
" Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival."7.69[Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996)
"The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells."7.67HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989)
"The DNA polymerase of human herpes viruses, including cytomegalovirus (CMV), and the reverse transcriptase of human immunodeficiency virus (HIV) are selectively inhibited in vitro by the pyrophosphate analogue foscarnet."6.17Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. ( Bryson, HM; Wagstaff, AJ, 1994)
"To evaluate the efficacy of foscarnet on HIV infection in patients with late-stage HIV disease and multiple drug resistance."5.12Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. ( Bossi, P; Boubezari, I; Calvez, V; Canestri, A; Caumes, E; Dominguez, S; Ghosn, J; Katlama, C; Ktorza, N; Marguet, F; Wirden, M, 2006)
"Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis."5.08Foscarnet decreases human immunodeficiency virus RNA. ( Furrer, H; Hirschel, B; Kaiser, L; Olmari, M; Perrin, L; Von Overbeck, J; Yerly, S, 1995)
"Foscarnet was administered by continuous intravenous infusion in 15 patients with the acquired immunodeficiency syndrome (AIDS) in an open, uncontrolled study."5.06The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. ( Faber, V; Gaub, J; Gerstoft, J; Hofmann, B; Lernestedt, JO; Lindhardt, BO; Mathiesen, LR; Pedersen, C; Poulsen, AG; Ulrich, K, 1987)
"During zidovudine and stavudine treatment, HIV-1 selects several mutations (thymidine-associated mutations, TAMs) in the reverse transcriptase gene that confer high- and moderate-levels of resistance, respectively, to these nucleoside reverse transcriptase inhibitors (NRTIs)."4.82Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). ( Goldschmidt, V; Marquet, R, 2004)
"Foscarnet is a pyrophosphate analogue with activity against herpesviruses, human immunodeficiency virus (HIV), and other RNA and DNA viruses."4.78Mechanism of action of foscarnet against viral polymerases. ( Crumpacker, CS, 1992)
" Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival."3.69[Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996)
"Disodium palmityl phosphonoformate, a novel lipid phosphoester of the anti HIV agent phosphonoformate (foscarnet), inhibits HIV replication in H9 cells and syncytia formation in MOLT-3 cells as effectively as foscarnet itself, as shown by dose-response data from assays for expression of p17 and p24 viral antigens and syncytia formation."3.68Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins. ( Bhongle, NN; Camaioni Neto, C; Piratla, RK; Sarin, PS; Steim, JM; Sun, DK; Turcotte, JG, 1990)
"The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells."3.67HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989)
" It is thus difficult to formulate optimal dosing regimens on the basis of what is known of foscarnet pharmacodynamics and pharmacokinetics."2.38Clinical pharmacology: foscarnet. ( Lietman, PS, 1992)
" The mean peak concentration in plasma following the intravenous administration of foscarnet (90 mg/kg) was 887."1.30Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients. ( Gazzard, BG; Higgs, CJ; Lant, AF; Martin-Munley, S; Noormohamed, FH; Youle, MS, 1998)
" The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive."1.28Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. ( Cheng, YC; Starnes, MC, 1989)

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-199013 (46.43)18.7374
1990's12 (42.86)18.2507
2000's3 (10.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schott, H1
Hamprecht, K1
Schott, S1
Schott, TC1
Schwendener, RA1
Goldschmidt, V1
Marquet, R1
Canestri, A1
Ghosn, J1
Wirden, M1
Marguet, F1
Ktorza, N1
Boubezari, I1
Dominguez, S1
Bossi, P1
Caumes, E1
Calvez, V1
Katlama, C1
Wagstaff, AJ1
Bryson, HM1
Bailey, JM1
Lightfoote, M1
Lillehoj, E1
Nelson, K1
Kaiser, L1
Perrin, L1
Hirschel, B1
Furrer, H1
Von Overbeck, J1
Olmari, M1
Yerly, S1
Soriano, V1
Mas, A1
Bravo, R1
Moreno, V1
González-Lahoz, J1
Noormohamed, FH1
Youle, MS1
Higgs, CJ1
Martin-Munley, S1
Gazzard, BG2
Lant, AF1
Tural, C1
Romeu, J1
Sirera, G1
Andreu, D1
Conejero, M1
Ruiz, S1
Jou, A1
Bonjoch, A1
Ruiz, L1
Arnó, A1
Clotet, B1
Crumpacker, CS1
Lietman, PS1
Tao, P1
Zhang, X1
Quan, K1
Cox, S1
Koshida, R1
Harmenberg, J1
Wahren, B1
Camaioni Neto, C1
Steim, JM1
Sarin, PS1
Sun, DK1
Bhongle, NN1
Piratla, RK1
Turcotte, JG1
Snoeck, R1
Lagneaux, L1
Delforge, A1
Bron, D1
Van der Auwera, P1
Stryckmans, P1
Balzarini, J1
De Clercq, E1
Vogt, M1
Schooley, RT1
Hirsch, MS1
Frank, KB1
McKernan, PA1
Smith, RA1
Smee, DF1
Wondrak, EM1
Löwer, J1
Kurth, R1
Larder, BA1
Darby, G1
Richman, DD1
Montefiori, DC1
Robinson, WE1
Mitchell, WM1
Starnes, MC1
Cheng, YC1
Crowe, SM1
McGrath, MS1
Elbeik, T1
Kirihara, J1
Mills, J2
Yarchoan, R1
Broder, S1
Jacobson, MA1
Crowe, S1
Levy, J1
Aweeka, F1
Gambertoglio, J1
McManus, N1
Bergdahl, S1
Sönnerborg, A1
Larsson, A1
Strannegard, O1
Weber, J1
Farthing, CF1
Dalgleish, AG1
Clark, A1
McClure, M1
Chanas, A1
Gaub, J1
Pedersen, C1
Poulsen, AG1
Mathiesen, LR1
Ulrich, K1
Lindhardt, BO1
Faber, V1
Gerstoft, J1
Hofmann, B1
Lernestedt, JO1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726]Phase 153 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for foscarnet and HIV

ArticleYear
Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs).
    The international journal of biochemistry & cell biology, 2004, Volume: 36, Issue:9

    Topics: Adenosine Triphosphate; DNA Primers; Drug Resistance, Multiple, Viral; Foscarnet; HIV; HIV Reverse T

2004
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Drugs, 1994, Volume: 48, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti

1994
Mechanism of action of foscarnet against viral polymerases.
    The American journal of medicine, 1992, Feb-14, Volume: 92, Issue:2A

    Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Interactions; Drug Resistance, Microbial; Fosca

1992
Clinical pharmacology: foscarnet.
    The American journal of medicine, 1992, Feb-14, Volume: 92, Issue:2A

    Topics: Antiviral Agents; Foscarnet; HIV; Humans; Nucleic Acid Synthesis Inhibitors; Phosphonoacetic Acid; R

1992
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
    Important advances in oncology, 1987

    Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace

1987

Trials

6 trials available for foscarnet and HIV

ArticleYear
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
    Antiviral therapy, 2006, Volume: 11, Issue:5

    Topics: Adult; Aged; CD4 Lymphocyte Count; Disease Progression; Drug Resistance, Multiple, Viral; Foscarnet;

2006
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Drugs, 1994, Volume: 48, Issue:2

    Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti

1994
Foscarnet decreases human immunodeficiency virus RNA.
    The Journal of infectious diseases, 1995, Volume: 172, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cyt

1995
[Chemotherapy and immunoprophylaxis of HIV infection].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1986, Nov-25, Volume: 75, Issue:48

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma

1986
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
    AIDS (London, England), 1987, Volume: 1, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Clinical Trials as Topic;

1987
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
    AIDS (London, England), 1987, Volume: 1, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Clinical Trials as Topic; Foscarnet; H

1987

Other Studies

18 other studies available for foscarnet and HIV

ArticleYear
Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
    Bioorganic & medicinal chemistry, 2009, Jan-01, Volume: 17, Issue:1

    Topics: Antiviral Agents; Cross-Linking Reagents; Cytomegalovirus; Drug Interactions; Foscarnet; Glyceryl Et

2009
Synthesis and antiviral properties of sterol phosphonoformates.
    Biochemical Society transactions, 1994, Volume: 22, Issue:3

    Topics: Antiviral Agents; Cholesterol Esters; Culture Techniques; Foscarnet; HIV; Humans; Phosphonoacetic Ac

1994
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet].
    Anales de medicina interna (Madrid, Spain : 1984), 1996, Volume: 13, Issue:8

    Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegaloviru

1996
Pharmacokinetics and absolute bioavailability of oral foscarnet in human immunodeficiency virus-seropositive patients.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:2

    Topics: Administration, Oral; Adult; Antiviral Agents; Biological Availability; Foscarnet; HIV; HIV Infectio

1998
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
    The Journal of infectious diseases, 1998, Volume: 177, Issue:4

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus

1998
The characterization of EIAV reverse transcriptase and its inhibition by 5'-triphosphates of 2'-deoxyuridine analogs, PFA and PAA.
    Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College = Chung-kuo i hsueh k'o hsueh yuan, Chung-kuo hsieh ho i k'o ta hsueh hsueh pao, 1990, Volume: 5, Issue:3

    Topics: Antiviral Agents; Dideoxynucleotides; Foscarnet; HIV; Infectious Anemia Virus, Equine; Phosphonoacet

1990
Synergistic combinations and peptides in the inhibition of human immunodeficiency virus.
    Advances in enzyme regulation, 1991, Volume: 31

    Topics: Alpha-Globulins; Amino Acid Sequence; Antiviral Agents; Cell Line; Dideoxynucleosides; Drug Synergis

1991
Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
    Biochemical and biophysical research communications, 1990, Aug-31, Volume: 171, Issue:1

    Topics: Antiviral Agents; Cell Fusion; Cell Line; Chemical Phenomena; Chemistry, Physical; Foscarnet; HIV; I

1990
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1990, Volume: 9, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome

1990
Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.
    Antimicrobial agents and chemotherapy, 1987, Volume: 31, Issue:9

    Topics: Antimetabolites; Antiviral Agents; Deoxyribonucleosides; Deoxyribonucleotides; Foscarnet; HIV; Organ

1987
Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
    The Journal of antimicrobial chemotherapy, 1988, Volume: 21, Issue:2

    Topics: Antiviral Agents; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; Foscarnet; HIV; In Vitro

1988
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Science (New York, N.Y.), 1989, Mar-31, Volume: 243, Issue:4899

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Fosca

1989
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
    AIDS research and human retroviruses, 1989, Volume: 5, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combi

1989
Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
    Virus genes, 1989, Volume: 2, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Dinucleoside Phosphates; DNA Replication; DN

1989
Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
    Journal of medical virology, 1989, Volume: 29, Issue:3

    Topics: Antiviral Agents; Dose-Response Relationship, Drug; Foscarnet; Gene Products, gag; HIV; HIV Antigens

1989
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    The Journal of infectious diseases, 1988, Volume: 158, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI

1988
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
    Lancet (London, England), 1988, May-07, Volume: 1, Issue:8593

    Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Foscarnet; HIV; HIV Antigens;

1988
AIDS: the virus, antivirals and vaccines.
    British journal of hospital medicine, 1987, Volume: 37, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans

1987